Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hofmann Anna, Saef Benjamin, Powell William J B, Paczynski Madeline, Ponisio Maria R, Vila-Castelar Clara, Posey Zachary, Oh Inez Y, Hofford Mackenzie R, Aldinger Melissa, Bateman Randall J, Raji Cyrus A, Benzinger Tammie L S, Cruchaga Carlos, Dow Alan, Buckley Rachel, Xiong Chengjie, Morris John C, Snider B Joy, Gupta Aditi, Schindler Suzanne E
Аннотация
INTRODUCTION: Usage of biomarker tests for Alzheimer's disease pathology and rates of positivity were assessed at the Washington University Memory Diagnostic Center.
METHODS: Patients who underwent at least one biomarker test for clinical purposes between June 2021 and March 2025 were included (n = 1136). Data were retrospectively extracted from electronic health records.
RESULTS: The median age was 73.2 years (52% female; 93% White). In total, 455 amyloid positron emission tomography (PET) scans, 505 cerebrospinal fluid tests, and 242 blood tests were performed. The number of biomarker tests increased seven-fold over the past 4 years. The rate of positivity was ≈70% across modalities. Higher rates of biomarker positivity were associated with older age, female sex, and White race; lower rates were associated with hypertension and diabetes.
DISCUSSION: Biomarker testing greatly increased following the approval of amyloid-targeting treatments. The overall rate of biomarker positivity was high and varied by demographic factors and medical comorbidities.
METHODS: Patients who underwent at least one biomarker test for clinical purposes between June 2021 and March 2025 were included (n = 1136). Data were retrospectively extracted from electronic health records.
RESULTS: The median age was 73.2 years (52% female; 93% White). In total, 455 amyloid positron emission tomography (PET) scans, 505 cerebrospinal fluid tests, and 242 blood tests were performed. The number of biomarker tests increased seven-fold over the past 4 years. The rate of positivity was ≈70% across modalities. Higher rates of biomarker positivity were associated with older age, female sex, and White race; lower rates were associated with hypertension and diabetes.
DISCUSSION: Biomarker testing greatly increased following the approval of amyloid-targeting treatments. The overall rate of biomarker positivity was high and varied by demographic factors and medical comorbidities.